BiologicsMD Uses Unique Fusion Proteins To Treat Alopecia Safely
Executive Summary
Emerging Company Profile: The US biotech is developing a series of recombinant fusion proteins to tackle alopecia and other diseases without supressing the immune system.
You may also be interested in...
Galecto Validates LOXL2 Targeting With Interim Myelofibrosis Phase II Success
The US biotech’s LOXL2 inhibitor candidate has reduced collagen fibrosis of the bone marrow in a small number of Phase II patients, helping validate a historically tricky approach attempted by few.
CTI’s Vonjo Shows Potential In Anemic Myelofibrosis Patients, Promising Further Market Growth
New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.
Pharming’s Leniolisib On Track To Become First Disease-Modifying APDS Drug
The Dutch firm’s US filing for its first-in-class PI3K inhibitor has been accepted under priority review, bringing the asset closer to becoming the first disease-modifying option for a rare, genetic disorder.